Morgan Stanley Upgrades Vertex (VRTX) to Overweight
VRTX Hot Sheet
Rating Summary:12 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Morgan Stanley upgrades Vertex Pharma (Nasdaq: VRTX) from Equalweight to Overweight. The firm set a $50 price target.
Traders seem to be cheering the upgrade in this morning's pre-market session: the stock most recently traded at $37.75, up 2.3% from yesterday's close. The firm's new price target represents potential upside of about 32%.
To see all the analyst calls on shares of Vertex, visit our Analyst Ratings page.
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.
Traders seem to be cheering the upgrade in this morning's pre-market session: the stock most recently traded at $37.75, up 2.3% from yesterday's close. The firm's new price target represents potential upside of about 32%.
To see all the analyst calls on shares of Vertex, visit our Analyst Ratings page.
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.
You May Also Be Interested In
- UPDATE: Auriga Upgrades Lifepoint Holdings (LPNT) to Buy; Use Recent Pullback As Opportunity
- Goldman Sachs Upgrades Teradyne (TER) to Buy
- UBS Raises Price Target and Estimates on PetSmart (PETM); Sees Sustained Sales and Margin Benefit
Create E-mail Alert Related Categories
UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
